Cardiol Therapeutics Could Be Sitting On A Breakthrough Therapy To Treat A Major Covid-19 Related Condition

Cardiol Therapeutics Could Be Sitting On A Breakthrough Therapy To Treat A Major Covid-19 Related Condition

Following the COVID pandemic, the level of safety in college sports has come under heavy scrutiny and has become one of the most highly talked about subjects.

One of the most significant health concerns that is associated with college athletes in the COVID era is Myocarditis, which is the inflammation of the heart muscle. So far, the illness has been found in at least five Big Ten Conference athletes as well as several other athletes in other conferences.

If the condition is left undiagnosed and untreated it can cause severe heart damage, sudden cardiac arrest, and could prove to be fatal. Although Myocarditis is a rare condition, COVID has been linked with the illness with a higher frequency than other viruses. This data is based on a limited number of studies and anecdotal evidence and is something that our readers should be aware of.

Catch CEO David Elsley Presenting Live @ The MoneyShow Virtual Events

Last month, we highlighted Cardiol Therapeutics (CRDL.TO; CRTPF.OTCQX) due to its focus on the development of innovative cannabidiol products for heart diseases such as Chronic Heart Failure and Acute Myocarditis. We believe that the company has been flying under the radar and is uniquely positioned to capitalize on illnesses that have a large total addressable market (TAM).

Cardiol has Several Major Avenues for Growth

Although COVID-19 is considered to be primarily a respiratory disease, there have been an increasing number of studies indicating that COVID patients are more likely to develop cardiovascular complications. This connection between patients and the disease has created an opportunity for Cardiol, and we believe that their business is positioned in the right place at the right time.

Last month, Cardiol reported filing a new patent application covering the use of CBD to improve the outcome of patients that have been diagnosed with COVID-19. The application includes the use of CBD to reduce the severity of disease in COVID-19 patients who have pre-existing cardiovascular conditions, and to prevent the progression of such conditions.

A recent study published in the Journal of the American Medical Association Cardiology showed that 35% of hospitalized COVID-19 patients had underlying cardiovascular disease (CVD). Other studies show that COVID-19 patients are more likely to develop cardiovascular complications even if they do not have pre-existing CVD.

Cardiol has been highly focused on this opportunity and a pre-clinical research study in a model involving cardiac injury demonstrated that Cardiol’s pharmaceutically produced CBD has a cardioprotective effect. The company’s product showed a reduction of fibrosis, cardiac hypertrophy (enlargement of the heart), and the cardiac re-modelling marker BNP.

A Biotech Growth Story that is Flying under the Radar

We believe that the increased awareness around Myocarditis will benefit Cardiol over the long-term and are of the opinion that the market has not taken this aspect of the story into account. At current levels, we believe that Cardiol has a compelling risk-reward profile and are bullish on the growth prospects that are associated with it.

Cardiol is led by a management team has been highly focused on the biotech side of the cannabis industry. If you look at companies like GW Pharmaceuticals (GWPH) which has a $4+ billion market cap or MyoKardia (MYOK) which has a $5 billion market cap, you will notice that these stocks took off when they announced positive clinical trial data. When it comes to bringing cannabis-based pharmaceutical drugs to market, GW set the stage for Cardiol and we see potential for Cardiol to become the GW Pharma of Heart Disease.

If you are interested in learning more about Cardiol Therapeutics Inc., please send an email to support@technical420.com to be added to our distribution list.

Pursuant to an agreement between StoneBridge Partners LLC and Cardiol Therapeutics Inc.  we have been hired for a period of 90 days beginning June 22, 2020 and ending September 22, 2020 to publicly disseminate information about (CRDL) including on the Website and other media including Facebook and Twitter. We are being paid $5,000 per month (CRDL) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero (0) shares of (CRDL), which we purchased in the open market. We plan to sell the “ZERO” shares of (CRDL) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (CRDL) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Wed, 19 Aug 2020 12:18:47 +0000